- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03497494
the Related Factors of Bariatric Surgery on Gastroesophageal Reflux Disease
Analysis the Related Factors of Bariatric Surgery on Gastroesophageal Reflux Disease and Its Prevention and Treatment: a Prospective, Multicenter and Randomized Controlled Study
Obesity and related metabolic diseases have become a chronic disease that is a threat to human health. Bariatric surgery can effectively and long-term reduce excess body weight and relieve related metabolic diseases, including type 2 diabetes. Laparoscopic gastric bypass surgery and laparoscopic sleeve gastrectomy are commonly used in bariatric surgery. Laparoscopic sleeve gastrectomy due to simple operation, good weight loss, and metabolic disease control effect, which is more widely used. However, there are several studies that show an increased chance of gastroesophageal reflux disease after laparoscopic sleeve gastrectomy. Long-term gastroesophageal reflux may lead to Barrett's esophagus or esophageal cancer. Nowadays, the cause of gastroesophageal reflux disease after sleeve gastrectomy is not clear and precautionary measures are not precise.
In this study, prospective randomized controlled trials were conducted to explore the possible causes of gastroesophageal reflux after sleeve gastrectomy and to explore ways to prevent gastroesophageal reflux disease after sleeve gastrectomy.
Studieoversikt
Status
Detaljert beskrivelse
With the social development and changes in the lifestyle, the incidence of obesity and type 2diabetes is rapidly increasing. In 2010, the global incidence of type 2 diabetes was 8.3% in adults, 11.6% in China and 50.1% in China. In overweight and obese people, the prevalence of type 2 diabetes also increased significantly, and the prevalence of type 2diabetes in those people with BMI> 30 reached 18.5-23%. Diabetes-induced cardiovascular and cerebrovascular diseases, renal insufficiency and other complications, seriously affecting the quality of life of the patients, endangering the safety of life, the treatment of type 2 diabetes and related complications to public health expenditure has brought tremendous pressure.
Traditional medical methods are difficult to achieve long-term and effective control of type 2 diabetes. Surgery has been shown to achieve 75-95% long-term relief of obesity in patients. Roux-en-Y gastric bypass (Roux-en-Y gastric bypass, RYGB) and laparoscopic sleeve gastrectomy are most commonly used. Among them, laparoscopic sleeve gastrectomy is relatively simple, low incidence of complications, lower operating costs, and gradually become the most important surgical methods of weight loss and metabolic disease surgery. Numerous clinical studies are shown that sleeve gastrectomy in patients with type 2 diabetes has the same therapeutic effect as gastric bypass with a complete remission rate of 70-90% for T2DM.
For the choice of surgical approach, numerous studies have shown that BMI ≧ 45, the general choice of gastric bypass surgery, BMI <45, participants can choose sleeve gastrectomy. The remission rate for T2DM, sleeve gastrectomy has a good result for young patients with shorter duration. In China, the BMI less than 45 is majorities.
According to the previous survey in 2012, the newly diagnosed diabetes patients in China constituted more than half of all diabetic patients. Since laparoscopic sleeve gastrectomy is relatively simple, so sleeve gastrectomy is easier to popularize in China and has wide application prospect.
As an invasive treatment, laparoscopic sleeve gastrectomy also presents opportunities of surgery-related complications, including gastric leak (0.5-1%), stenosis (0.1-0.5%), bleeding (about 0.5%), and gastroesophageal reflux disease (GERD). Gastroesophageal reflux disease is a most common upper gastrointestinal disease, numerous clinical studies shown that the incidence of GERD in western populations are 10-20%, while obese people are around 37-72%, if abdominal fat accumulation more obvious, the incidence of GERD will become higher. In China, there is still no relevant data. Gastric bypass surgery has a clear effect on the treatment of GERD, and the relationship between sleeve gastrectomy and GERD is still controversial. Some studies have shown that sleeve gastrectomy did not increase the incidence of postoperative GERD, while another study showed that the incidence of GERD after sleeve gastrectomy increased significantly. In addition, no studies have revealed the reasons for the occurrence of GERD after sleeve gastrectomy and no study showed how to prevent the occurrence of GERD after sleeve gastrectomy.
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510630
- The frist affiliated hospital of Jinan University
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- For the choice of surgical approach, numerous studies have shown that BMI ≧ 45, the general choice of gastric bypass surgery, BMI <45, you can choose sleeve gastrectomy. The remission rate for T2DM, sleeve gastrectomy has a good result for young patients with shorter duration. In our country, the BMI less than 45 is majorities.
Exclusion Criteria:
- BMI<27.5
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Without hiatal suture
the different distance of pylorus without hiatal suture
|
2 cm away from the pylorus edge
4 cm away from the pylorus edge
6 cm away from the pylorus edge
laparoscopic Roux-en-Y gastric bypass
Andre navn:
|
|
Aktiv komparator: With hiatal suture
the different distance of pylorus without hiatal suture
|
2 cm away from the pylorus edge
4 cm away from the pylorus edge
6 cm away from the pylorus edge
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
GERD-Health Related Quality of Life Questionnaire
Tidsramme: 1 year
|
Total Score: Calculated by summing the individual scores to questions 1-15.
|
1 year
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
preoperative and postoperative of abdominal ultrasound to examine the abdominal fat thickness
Tidsramme: 1 year
|
abdominal fat thickness in centimeter
|
1 year
|
|
Preoperative and postoperative BMI
Tidsramme: 1 year
|
The patient's weight and height will be combined to report BMI in kg/m^2
|
1 year
|
|
Preoperative and postoperative waist circumference
Tidsramme: 1 year
|
waist circumference in centimeter
|
1 year
|
|
Preoperative and postoperative abdominal circumference
Tidsramme: 1 year
|
abdominal circumference in centimeter
|
1 year
|
|
Preoperative and postoperative chest circumference
Tidsramme: 1 year
|
chest circumference in centimeter
|
1 year
|
|
Preoperative and postoperative neck circumference
Tidsramme: 1 year
|
neck circumference in centimeter
|
1 year
|
|
Preoperative and postoperative bone mineral density
Tidsramme: 1 year
|
bone mineral density in percentage
|
1 year
|
|
Preoperative and postoperative body fat measured
Tidsramme: 1 year
|
body fat measured in percentage
|
1 year
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- FirstJinanU20180120
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Gastroøsofageal refluks
-
Zagazig UniversityAktiv, ikke rekrutterendeGastro -oesophagal reflux | SpiseatferdsforstyrrelserEgypt
-
Cleveland Clinic LondonPåmelding etter invitasjonLaryngofaryngeal refluks | Gastro -oesophagal refluxDe forente arabiske emirater, Østerrike, Italia, Serbia, Sveits, Tyrkia (Türkiye), Storbritannia
-
Aplos MedicalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) og andre samarbeidspartnereAktiv, ikke rekrutterende
-
Dartmouth-Hitchcock Medical CenterTilbaketrukketGastro Esophageal Reflux Disease PPI Ikke-respondere
-
Astellas Pharma Global Development, Inc.TilgjengeligMetastatisk Gastroøsofageal Junction (GEJ) Adenocarcinoma | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer | Lokalt avansert ikke-opererbar gastrisk adenokarsinomkreft | Metastatisk gastrisk adenokarsinomkreftTyskland, Forente stater, Brasil, Frankrike, Singapore, Sør -Korea
-
Hoffmann-La RocheBioLineRx, Ltd.; Halozyme TherapeuticsFullførtGastrisk Adenocarcinoma eller Gastroesophageal Junction Adenocarcinoma eller Esophageal CarcinomaForente stater, Storbritannia, Australia, Taiwan, Israel, Spania, Sør -Korea
-
Universitair Ziekenhuis BrusselUkjentAcid Reflux Esofagitt | Ikke-sur refluks-øsofagittBelgia
-
Tianjin Medical University Cancer Institute and...FullførtGastrisk Adenocarcinoma eller Gastroesophageal Junction Adenocarcinoma eller Esophageal Carcinoma | Kreft og endetarmskreftKina
-
Centre Leon BerardHar ikke rekruttert ennåGastrisk Adenocarcinoma eller Gastroesophageal Junction Adenocarcinoma eller Esophageal Carcinoma | Ikke-metastatisk sykdomFrankrike
-
Fudan UniversityHar ikke rekruttert ennåGastrisk adenokarsinom | Peritoneal metastase | Gastrisk Adenocarcinoma eller Gastroesophageal Junction Adenocarcinoma eller Esophageal Carcinoma
Kliniske studier på 2 cm away from the pylorus edge
-
Mansoura UniversityFullført
-
Beijing Friendship HospitalPeking Union Medical College Hospital; Beijing Tiantan Hospital; Beijing... og andre samarbeidspartnereFullført
-
Fundació Institut de Recerca de l'Hospital de la...Ukjent